LIQUIDITY (Details) - USD ($) $ in Thousands, shares in Millions |
2 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Jan. 31, 2019 |
Aug. 31, 2019 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| Net loss | $ (30,446) | $ (29,862) | ||
| Net cash used in operating activities | (15,304) | (14,113) | ||
| Accumulated deficit | (126,903) | (94,184) | ||
| Cash and cash equivalents | 11,573 | 1,646 | ||
| Liabilities | 10,500 | $ 6,464 | ||
| Cash proceeds from equity offering | $ 25,000 | $ 22,600 | ||
| Aggregate principal balance | 5,300 | |||
| Accrued interest | $ 800 | |||
| Licensing obligations | 8,500 | |||
| Research and development spending and other clinical programs | 11,000 | |||
| Spending on compensation, benefits, rent, other research costs, and public company costs for auditing and professional fees | $ 10,400 | |||
| Subsequent Event [Member] | ||||
| Net proceeds from private placement | $ 22,600 | |||
| Number of shares issued | 82.9 | |||
| X | ||||||||||
- Definition Represents the amount of proceeds from issuance of private placement net of advisory fees payable. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development expenses and other clinical program costs. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. No definition available.
|
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The compensation expense recognized during the period pertaining to the deferred compensation arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest payable on debt, including, but not limited to, trade payables. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|